相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cancer Statistics, 2014
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2014)
Phase III Study Comparing Amrubicin Plus Cisplatin With Irinotecan Plus Cisplatin in the Treatment of Extensive-Disease Small-Cell Lung Cancer: JCOG 0509
Miyako Satouchi et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study
Kaoru Kubota et al.
LANCET ONCOLOGY (2014)
Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial
M. Reck et al.
ANNALS OF ONCOLOGY (2013)
A phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer
Ji-Youn Han et al.
LUNG CANCER (2013)
Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer
Charles M. Rudin et al.
CLINICAL CANCER RESEARCH (2012)
Cigarette smoking and lung cancerurelative risk estimates for the major histological types from a pooled analysis of case-control studies
Beate Pesch et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Carboplatin- or Cisplatin-Based Chemotherapy in First-Line Treatment of Small-Cell Lung Cancer: The COCIS Meta-Analysis of Individual Patient Data
Antonio Rossi et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Clinical Significance and Molecular Characteristics of Circulating Tumor Cells and Circulating Tumor Microemboli in Patients With Small-Cell Lung Cancer
Jian-Mei Hou et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Topotecan/Cisplatin Compared with Cisplatin/Etoposide as First-Line Treatment for Patients with Extensive Disease Small-Cell Lung Cancer Final Results of a Randomized Phase III Trial
Thomas H. Fink et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer
Charles M. Rudin et al.
NATURE GENETICS (2012)
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
Martin Peifer et al.
NATURE GENETICS (2012)
A framework for identification of actionable cancer genome dependencies in small cell lung cancer
Martin L. Sos et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1
Lauren Averett Byers et al.
CANCER DISCOVERY (2012)
Phase I Clinical Study of Seneca Valley Virus (SVV-001), a Replication-Competent Picornavirus, in Advanced Solid Tumors with Neuroendocrine Features
Charles M. Rudin et al.
CLINICAL CANCER RESEARCH (2011)
Progression-Free Survival Ratio As End Point for Phase II Trials in Advanced Solid Tumors Reply
Daniel D. Von Hoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Randomized Phase II Study of Bevacizumab in Combination With Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer: Results From the SALUTE Trial
David R. Spigel et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Randomized Phase II Trial of Single-Agent Amrubicin or Topotecan as Second-Line Treatment in Patients With Small-Cell Lung Cancer Sensitive to First-Line Platinum-Based Chemotherapy
Robert Jotte et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Phase II Trial of Sunitinib Maintenance Therapy After Platinum-Based Chemotherapy in Patients with Extensive-Stage Small Cell Lung Cancer
Bryan J. Schneider et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
A Phase II Study of AT-101 (Gossypol) in Chemotherapy-Sensitive Recurrent Extensive-Stage Small Cell Lung Cancer
Maria Q. Baggstrom et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer
Paul K. Paik et al.
LUNG CANCER (2011)
A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease
P. Zatloukal et al.
ANNALS OF ONCOLOGY (2010)
Phase II Trial of Imatinib Maintenance Therapy After Irinotecan and Cisplatin in Patients With c-Kit-Positive, Extensive-Stage Small-Cell Lung Cancer
Bryan J. Schneider et al.
CLINICAL LUNG CANCER (2010)
Phase II Study of Amrubicin As Second-Line Therapy in Patients With Platinum-Refractory Small-Cell Lung Cancer
David S. Ettinger et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II Study of Cediranib (AZD 2171), an Inhibitor of the Vascular Endothelial Growth Factor Receptor, for Second-Line Therapy of Small Cell Lung Cancer (National Cancer Institute #7097)
Suresh S. Ramalingam et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
A Phase II Study of Dasatinib in Patients with Chemosensitive Relapsed Small Cell Lung Cancer (Cancer and Leukemia Group B 30602)
Antonius A. Miller et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
A Meta-Analysis of Randomized Controlled Trials Comparing Irinotecan/Platinum with Etoposide/Platinum in Patients with Previously Untreated Extensive-Stage Small Cell Lung Cancer
Jingwei Jiang et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Phase II Study of the Histone Deacetylase Inhibitor Romidepsin in Relapsed Small Cell Lung Cancer (Cancer and Leukemia Group B 30304)
Gregory A. Otterson et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Camptothecins Compared with Etoposide in Combination with Platinum Analog in Extensive Stage Small Cell Lung Cancer Systematic Review with Meta-Analysis
Joao Paulo S. N. Lima et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Sorafenib in Platinum-Treated Patients with Extensive Stage Small Cell Lung Cancer A Southwest Oncology Group (SWOG 0435) Phase II Trial
Barbara J. Gitlitz et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Maintenance or consolidation therapy in small-cell lung cancer: A systematic review and meta-analysis
Antonio Rossi et al.
LUNG CANCER (2010)
Retrospective analysis of efficacy and safety of amrubicin in refractory and relapsed small-cell lung cancer
Tsuneo Shimokawa et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II trial of fenretinide (NSC 374551) in patients with recurrent small cell lung cancer
Bryan J. Schneider et al.
INVESTIGATIONAL NEW DRUGS (2009)
Phase III Trial of Irinotecan/Cisplatin Compared With Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results From SWOG S0124
Primo N. Lara et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Anti-angiogenic Therapy Using Thalidomide Combined With Chemotherapy in Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial
Siow Ming Lee et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer:: A Randomized phase III trial
Andreas Hermes et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Randomized phase II study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer:: CALGB 30103
Charles M. Rudin et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Randomized Phase II Trial Comparing Amrubicin With Topotecan in Patients With Previously Treated Small-Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 0402
Akira Inoue et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: A randomized trial
Serge Leyvraz et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
The International Association for the study of Lung Cancer - Lung Cancer staging project: Proposals regarding the clinical staging of small cell Lung Cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for Lung Cancer
Frances A. Shepherd et al.
JOURNAL OF THORACIC ONCOLOGY (2007)
A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: A trial of the eastern cooperative oncology group (E1500)
Kishan J. Pandya et al.
JOURNAL OF THORACIC ONCOLOGY (2007)
Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada clinical trials group study BR. 20
Andrew M. Arnold et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy:: An intergroup study FNCLCC cleo04-IFCT 00-01
Jean Louis Pujol et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Prophylactic cranial irradiation in extensive small-cell lung cancer
Ben Slotman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Evaluation of the recommended dose and efficacy of amrubicin as second- and third-line chemotherapy for small cell lung cancer
Satoshi Igawa et al.
JOURNAL OF THORACIC ONCOLOGY (2007)
The IASLC lung cancer staging project: Proposals for the revision of he TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours
Peter Goldstraw et al.
JOURNAL OF THORACIC ONCOLOGY (2007)
Randomized phase II study of maintenance vandetanib (ZD6474) in small cell lung cancer (SCLC) patients who have a complete or partial response to induction therapy: NCIC CTG BR.20
A. M. Arnold et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study
Takashi Yana et al.
INVESTIGATIONAL NEW DRUGS (2007)
Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic oncology research group study 0301
Sayaka Onoda et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer
Mary E. R. O'Brien et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: Analysis of the surveillance, epidemiologic, and end results database
Ramaswamy Govindan et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer
JR Eckardt et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer
A Schmittel et al.
ANNALS OF ONCOLOGY (2006)
Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: A Hoosier Oncology Group phase II trial
AM Moore et al.
LUNG CANCER (2006)
Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-0897113; Silva Study)
G Giaccone et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and leukemia group B trial 9732
HB Niell et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer
P Lorigan et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancer
Y Ohe et al.
ANNALS OF ONCOLOGY (2005)
Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer
JV Heymach et al.
ANNALS OF ONCOLOGY (2004)
Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer
DB Fried et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: Results from a randomized phase III trial with 5 years' follow-up
S Sundstrom et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patinets with small-cell lung cancer: A trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organisation for the Research and Treatment of Cancer
FA Shepherd et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer
W Noda et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593 - A phase III trial of the Eastern Cooperative Oncology Group
JH Schiller et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Phase II trial of paclitaxel and carboplatin in metastatic small-cell lung cancer:: A Groupe Francais de Pneumo-Cancerologie Study
P Thomas et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis
C Mascaux et al.
LUNG CANCER (2000)
分享论文
